Amicus Therapeutics Files 8-K on Financials

Ticker: FOLD · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateNov 4, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

Amicus Therapeutics dropped an 8-K on Nov 4th - check it for financial updates.

AI Summary

On November 4, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This 8-K filing indicates that Amicus Therapeutics is providing an update on its financial performance and condition to the SEC. Investors and stakeholders will look to this report for key financial details and operational insights.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting routine financial information and does not appear to contain any immediate material adverse events.

Key Players & Entities

  • Amicus Therapeutics, Inc. (company) — Registrant
  • November 4, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-33497 (identifier) — Commission File Number
  • 71-0869350 (identifier) — I.R.S. Employer Identification No.
  • 47 Hulfish Street, Princeton, New Jersey 08542 (address) — Principal Executive Offices
  • 609 - 662-2000 (phone_number) — Registrant's Telephone Number

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not contain the specific details of these results or updates.

What is the primary purpose of this 8-K filing for Amicus Therapeutics?

The primary purpose is to report on the company's results of operations and financial condition, and to file financial statements and exhibits as required by the SEC.

When was this 8-K filing submitted to the SEC?

The filing was submitted on November 4, 2025, which is also the date of the earliest event reported.

In which state is Amicus Therapeutics incorporated?

Amicus Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Amicus Therapeutics?

The principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.

Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-11-04 07:39:10

Key Financial Figures

  • $0.01 — ich registered Common Stock Par Value $0.01 FOLD NASDAQ Indicate by check mar

Filing Documents

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on November 4, 2025 to discuss its third quarter results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated November 4, 2025 99.2 November 4, 2025 Conference Call Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: November 4, 2025 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.